ÇѸ²´ëÇб³¼º½Éº´¿ø

±è¹üÁØ ±³¼ö

031-380-3704 getwisdom1025@hallym.or.kr
  • Áø·á°ú Ç÷¾×Á¾¾ç³»°ú

Àü¹®Áø·áºÐ¾ß

¼ÒÈ­±â¾Ï(½Äµµ¾Ï, °£´ãµµÃéÀå¾Ï, À§¾Ï, ´ëÀå¾Ï µî) ¹× ±âŸ ¾ÏÁúȯ, ¾ç¼ºÇ÷¾×Áúȯ(ºóÇ÷, Ç÷¼ÒÆÇ ¹× ¹éÇ÷±¸ Áúȯ)

ÀüÈ­ ¿¹¾à 1577-1801
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2022-08-15 ~ 2022-08-20)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü
¿ÀÈÄ ¿Ü·¡Áø·á¿Ü·¡Áø·á¿Ü·¡Áø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

ÇѸ²´ëÇб³ Àǰú´ëÇÐ Çлç

ÇѸ²´ëÇб³ Àǰú´ëÇÐ ¹Ú»ç

ÇѸ²´ëÇб³ Àǰú´ëÇÐ ¼®»ç

°æ·Â

°æ·Â

¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú ÀüÀÓÀÇ

ÇѸ²´ëÇб³ °­³²¼º½Éº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀüÀÓÀÇ

ÇѸ²´ëÇб³¼º½Éº´¿ø ÀÎÅÏ, ³»°ú Àü°øÀÇ

±¹±º¼öµµº´¿ø Ç÷¾×Á¾¾ç³»°ú Áß°ßÀÇ

ÇѸ²´ëÇб³¼º½Éº´¿ø Ç÷¾×Á¾¾ç³»°ú Á¶±³¼ö

ÇÐȸȰµ¿

ÇÐȸȰµ¿

´ëÇѳ»°úÇÐȸ Á¤È¸¿ø

Çѱ¹ÀÓ»ó¾ÏÇÐȸ Á¤È¸¿ø

´ëÇÑÇ׾Ͽä¹ý¿¬±¸È¸ Á¤È¸¿ø

´ëÇѾÏÇÐȸ Á¤È¸¿ø

´ëÇÑÇ÷¾×ÇÐȸ Á¤È¸¿ø

¼ö»óÀÌ·Â

¼ö»óÀÌ·Â

¿ÃÇØÀÇ ¿¬±¸ÀÚ»ó, ±¹±º¼öµµº´¿ø (2017)

ÇѸ²Çмú»ó, ÃÖ¿ì¼ö»ó (2018)

³í¹®

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) (Therapeutic advances in medical oncology)

The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials (Indian journal of cancer)

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) (Therapeutic Advances in Medical Oncology)

Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification (INVESTIGATIONAL NEW DRUGS)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin / ^^¿µ¹® Á¦¸ñÀ» ¹Ýµå½Ã ±âÀçÇϽñ⠹ٶø´Ï´Ù. (cancer research and treatment)